Home Newsfeeds Jefferies Maintains Buy on Netflix, Raises Price Target to $400

Jefferies Maintains Buy on Netflix, Raises Price Target to $400

Jefferies analyst Andrew Uerkwitz maintains Netflix (NASDAQ:NFLX) with a Buy and raises the price target from $385 to $400.

byBenzinga Newsdesk

January 20, 2023

1 minute read

Jefferies analyst Andrew Uerkwitz maintains Netflix (NASDAQ:NFLX) with a Buy and raises the price target from $385 to $400.

Analyst Ratings

Where Summit Materials Stands With Analysts

By Benzinga Insights

September 12, 1:00 PM

Over the past 3 months, 13 analysts have published their opinion on Summit Materials (NYSE:SUM) stock. These analysts…

SUM

Pfizer, European Pharma Firms Collaborate With European Commission For Future Health Emergency Preparedness

By Vandana Singh

June 30, 2:06 PM

The European Commission has reportedly made arrangements with Pfizer Inc (NYSE: PFE) and various European pharmaceutical companies to secure the capacity to produce up to 325 million vaccines annually for potential future global health crises.

BNTX

eFFECTOR Therapeutics Announces $15M Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

By Benzinga Newsdesk

January 25, 9:11 AM

eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) (the "Company"), a leader in the development of selective translation regulator inhibitors ("STRIs") for the treatment of cancer, today announced that it has entered into a

EFTR

JNJ’s Consumer Health Business Separation Will Remove Uncertainty Cloud From Company: Why This Analyst Wants Visibility

By Vandana Singh

March 1, 3:55 PM

Guggenheim initiated the coverage on Johnson & Johnson (NYSE:JNJ) with a Neutral rating and a $161 price target. The analyst agrees with the…

JNJ

Jefferies Maintains Buy on Netflix, Raises Price Target to $400

Related Posts

Where Summit Materials Stands With Analysts

Pfizer, European Pharma Firms Collaborate With European Commission For Future Health Emergency Preparedness

eFFECTOR Therapeutics Announces $15M Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

JNJ’s Consumer Health Business Separation Will Remove Uncertainty Cloud From Company: Why This Analyst Wants Visibility